echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The second!

    The second!

    • Last Update: 2021-12-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    Author: Sunshine

    On December 22, the official website of CDE showed that the marketing application of Livzon Pharmaceutical Tocilizumab was accepted by the State Food and Drug Administration


    Tocilizumab injection (tocilizumab) was developed by Chugai Pharmaceutical (Roche).


    Since February 2009, tocilizumab has been approved for marketing in many countries and regions such as the European Union, the United States, Japan, and China.


    Source: NextPharma

    At present, there are 3 indications approved in China for the research of tocilizan antigen, namely: adult rheumatoid arthritis, systemic juvenile idiopathic arthritis and cytokine release syndrome


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.